Evidence map›Paper›PMID 40075107›Full record

ArticleScientific reports2025

Periplaneta americana extract improves recurrent oral ulcers through regulation of TLR4/NF-κB and Nrf2/HO-1 pathways.

Weijun Li, Yi Chen, Kailing Li, Zhongze Chen, Jingyu Zhang, Guanhua Zhao, Fanfan Sun, Peiyun Xiao, Yongshou Yang

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Ultra-short cyclic peptide CyZoological research · 2025
    Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Weijun Li *Engineering Research Center for Development of the Periplaneta Americana Industry of Yunnan Provincial Department of Education, Dali University, Dali, 671000, Yunnan, China.
Yi Chen *Engineering Research Center for Development of the Periplaneta Americana Industry of Yunnan Provincial Department of Education, Dali University, Dali, 671000, Yunnan, China.
Kailing LiCollege of Pharmacy, Dali University, Dali, 671000, Yunnan, China.
Zhongze ChenEngineering Research Center for Development of the Periplaneta Americana Industry of Yunnan Provincial Department of Education, Dali University, Dali, 671000, Yunnan, China.
Jingyu ZhangCollege of Pharmacy, Dali University, Dali, 671000, Yunnan, China.
Guanhua ZhaoEngineering Research Center for Development of the Periplaneta Americana Industry of Yunnan Provincial Department of Education, Dali University, Dali, 671000, Yunnan, China.
Fanfan SunEngineering Research Center for Development of the Periplaneta Americana Industry of Yunnan Provincial Department of Education, Dali University, Dali, 671000, Yunnan, China.
Peiyun XiaoEngineering Research Center for Development of the Periplaneta Americana Industry of Yunnan Provincial Department of Education, Dali University, Dali, 671000, Yunnan, China. xiaopeiyun@dali.edu.cn.
Yongshou YangCollege of Pharmacy, Dali University, Dali, 671000, Yunnan, China. yangyongshou@dali.edu.cn.

Funding

Basic Research Projects of Local Undergraduate Universities in Yunnan Province 2019FH001(-034)The National Natural Science Foundation of China 82060747The Yunnan Expert Workstation 202405AF140044
6 · The paper itself

Abstract

Recurrent oral ulcers (ROUs) of oral mucosa disease are difficult to cure and relapse easily, and immune imLbalance or dysfunction is considered an essential factor in their occurrence and recurrence. Periplaneta americana extract (PAD), a raw material used in Kangfuxin Liquid and Yunnan Baiyao toothpaste, contains a variety of growth factors such as polypeptides and sticky sugar amino acids that promote tissue repair; this can encourage the growth of the granulation tissue and reduce inflammation on the wound surface. This study aimed to investigate the interventional potential of PAD on recurrent oral ulcers in rats and to elucidate the underlying mechanism of action involving the TLR4/NF-κB and Nrf2/HO-1 signaling pathways. A rat model of recurrent oral ulcer (ROU) was established using an oral antigen emulsifier. Rats in the ROU group were administered PAD by gavage for 7 days. To observe the effect of PDA on ROU mice. HE staining revealed that PAD restored the structure of the oral mucosal tissue and reduced inflammatory infiltration. FCM revealed that PAD upregulated CD3 + and CD4 + levels and the CD4 + /CD8 + ratio in peripheral blood T lymphocytes. ELISA revealed that PAD increased the content of IgA, IgG, IgM, VEGF, IL-2, and IL-10, while decreasing IL-6 and TNF-α content. Microplate analysis revealed that PAD significantly increased CAT content in the serum of ROU rats and reduced GSH, NO, SOD, and MDA levels. IHC staining, RT-qPCR, and Western blotting revealed that PAD downregulated Keap1 and IκBα expression, inhibited the TLR4/NF-κB signaling pathway, upregulated Nrf2 and HO-1 expression, and activated the Nrf2/HO-1 signaling pathway. These fndings suggest that PAD improved immune imbalance and oxidative stress in ROU rats by activating the Nrf2/HO-1 pathway and inhibiting the TLR4/NF-κB signaling pathway, thereby promoting the healing of oral ulcer wounds.

Indexed as

Heme Oxygenase-1NF-E2-Related Factor 2Oral UlcerPeriplanetaSignal TransductionToll-Like Receptor 4AnimalsDisease Models, AnimalMaleMouth MucosaNF-kappa BRatsRats, Sprague-DawleyHeme Oxygenase-1Nfe2l2 protein, ratNF-E2-Related Factor 2NF-kappa BTlr4 protein, ratToll-Like Receptor 4Immune regulationNrf2/HO-1 signaling pathwayPeriplaneta americana extractRecurrent oral ulcerTLR4/NF-κB signaling pathway

Identifiers

PMID40075107
PMCPMC11903863

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.